Clinical Trial Update: SYS6010 Combined With Enlonstobart In Recurrent Or Metastatic Head And Neck Squamous Cell Carcinoma [Phase 2]

View source ↗

Summary

A Phase 2 clinical trial update assessing SYS6010 in combination with Enlonstobart for recurrent or metastatic head and neck squamous cell carcinoma; the study …

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Head and Neck Squamous Cell Carcinoma

Drugs mentioned

• Enlonstobart
• SYS6010

Snippet

Sponsor: CSPC Megalith Biopharmaceutical Co.,Ltd. | Conditions: Head and Neck Squamous Cell Carcinoma | Phase 2 | Status: RECRUITING